Drawing for BACHEM PIONEERING PARTNER FOR PEPTIDES

USPTO serial 79147352

BACHEM PIONEERING PARTNER FOR PEPTIDES

Reviewed by CopyMark Law Group

Reg. 4741293Status 404
Filing date
Status date
Registration date
May 26, 2015
Examiner
RAPPAPORT, SETH
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BACHEM PIONEERING PARTNER FOR PEPTIDES?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Alex R Sluzas

Alex R Sluzas Paul and Paul1717 Arch StreetSuite 3740Philadelphia, PA 19103

Goods and services

ClassDescriptionStatusFirst use
001Chemicals for use in industry and science, namely, amino acids, peptides, reagents for peptide synthesis, amino acid derivatives, cytokines, enzyme inhibitors, enzyme substrates, growth factors, peptide substrates, all for use as scientific and laboratory research reagents in the field of medicine and molecular biology; pharmaceutical intermediates for use in the further manufacture of pharmaceuticals; chemical products used for preserving foodstuffsSECTION 71 - CANCELLED—
005Pharmaceutical and veterinary products, namely, pharmaceutical preparations for use in the treatment of bleeding, premature labor, pulmonary hypertension, erectile disfunction, coronary syndromes, prostate cancer, endometriosis, central precocious puberty, uterine myoma, osteoporosis, hypercalcernia, Paget's disease, reflex sympathetic dystrophy, nocturnal enureses, central diabetes insipidus, polyuria, polydipsia, hemophilia A, von Willebrand disease, unstable angina, myocardial infarction, hypoglycemia, ovarian follicular cysts, cryptochism, breast cancer, growth hormone deficiency, acromegaly, carcinoid syndrome, thyrotrophic adenomas, diabetes II, VIPosmas, ulcer bleeding, hemorrhagic gastritis, postoperative pancreatic and duodenal fistulae, variceal hemorrhage, neurological diseases, rheumatic diseases, skin diseases, diseases of the intestinal tract, cancer, conjunctivitis, glaucoma, ocular hypertension, Parkinson's disease, transfusion-induced hemosiderosis, candidasis, dermatophytosis, pityriasis, congenital homocystinuria, hyperammonaemia, hepatic encephalopathy, ischemic heart disease, chorioretinal vascular disorders, hypertension, endema, insomnia, bipolar disorder, and schizophrenia; pharmaceutical preparations for use in the diagnosis of gastrinoma; veterinary preparations for use in the induction of ovulation in estrous mares, and reproduction control in dogs and cats; pharmaceutical preparations for use in the diagnosis of Cushing's syndrome, hypothalamic-pituitary-gonadal axis function, growth hormone deficiency, pancreatic exocrine dysfunction, gastrinoma, and adrenocortical insufficiency; dietetic food and substances for medical or veterinary use, namely, taste-modulating food additives in the nature of peptides for medical use, appetite suppressors for medical use; food supplements for humans and animals; fungicides; herbicidesSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 1, 2024DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Nov 1, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 24, 2022INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Sep 22, 2022INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Sep 22, 2022INPCINVALIDATION PROCESSED—
Aug 10, 2022INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Dec 10, 2021C71TCANCELLED SECTION 71—
May 26, 2020REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Feb 1, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
Oct 30, 2015FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 24, 2015FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 24, 2015FIMPFINAL DISPOSITION PROCESSED—
Aug 26, 2015FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
May 26, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 10, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 10, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 6, 2015GPNXNOTIFICATION PROCESSED BY IB—
Feb 18, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Feb 18, 2015OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Feb 18, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 30, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jan 29, 2015ALIEASSIGNED TO LIE—
Jan 9, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 9, 2015XAECEXAMINER'S AMENDMENT ENTERED—
Jan 9, 2015GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 9, 2015GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 9, 2015CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 8, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 8, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 8, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 8, 2014RFNTREFUSAL PROCESSED BY IB—
Jul 23, 2014RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jul 23, 2014RFRRREFUSAL PROCESSED BY MPU—
Jul 18, 2014RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jul 17, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 17, 2014DOCKASSIGNED TO EXAMINER—
Jun 3, 2014MAFRAPPLICATION FILING RECEIPT MAILED—
May 30, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 29, 2014REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance